Early high-titer plasma therapy to prevent severe Covid-19 in older adults
- Libster, Romina Paula
- Pérez Marc, Gonzalo
- Wappner, Diego
- Coviello, Silvina Andrea
- Bianchi, Alejandra
- Braem, Virginia
- Esteban, Ignacio
- Caballero, Mauricio Tomás
- Wood, Cristian
- Berrueta, Mabel
- Rondan, Aníbal
- Lescano, Gabriela Mariel
- Cruz, Pablo
- Ritou, Yvonne
- Fernández Viña, Valeria Silvina
- Álvarez Paggi, Damián Jorge
- Esperante, Sebastian
- Ferreti, Adrián
- Ofman, Gaston
- Ciganda, Álvaro
- Rodriguez, Rocío
- Lantos, Jorge
- Valentini, Ricardo
- Itcovici, Nicolás
- Hintze, Alejandra
- Oyarvide, M. Laura
- Etchegaray, Candela
- Neira, Alejandra
- Name, Ivonne
- Alfonso, Julieta
- López Castelo, Rocío
- Caruso, Gisela
- Rapelius, Sofía
- Alvez, Fernando
- Etchenique, Federico
- Dimase, Federico
- Alvarez, Darío
- Aranda, Sofía S.
- Sánchez Yanotti, Clara Inés
- De Luca, Julián
- Jares Baglivo, Sofía
- Laudanno, Sofía
- Nowogrodzki, Florencia
- Larrea, Ramiro
- Silveyra, María
- Leberzstein, Gabriel
- Debonis, Alejandra
- Molinos, Juan
- González, Miguel
- Perez, Eduardo
- Kreplak, Nicolás
- Pastor Argüello, Susana
- Gibbons, Luz
- Althabe, Fernando
- Bergel, Eduardo
- Polack, Fernando Pedro
DOIAbstract
BACKGROUND: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. METHODS We conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms. The primary end point was severe respiratory disease, defined as a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing amb...
Add to ORKG